KORTUC CEO, Kazu Matsuda has been in the biopharmaceutical/healthcare technology business for over 20 years. As a CEO and CFO, he led several startup projects including antibody technology startup, Perseus Proteomic (sold to FujiFilm) as well as financial technology businesses. Before his involvement in the startup business, he spent over 10 years with Mitsubishi Corporation and Merrill Lynch (corporate finance and M&A for pharma/healthcare industry).
Kazu Matsuda graduated from University of Tokyo with a degree of Economics and obtained MBA from INSEAD.
The inventor of KORTUC (Code name: KRC-01) and an emeritus professor at Kochi University, Dr. Yasuhiro Ogawa is a radiation oncologist and has been at the front of cancer radiotherapy for over 30 years.
In 1988 he was engaged in research of breast conserving therapy as the most advanced treatment at that time in British Columbia Cancer Agency (BCCA) in Canada, which led him to establish a curative breast conserving therapy. After 10 years of research, he invented a new radiotherapy using hydrogen peroxide as radiosensitizer named “KORTUC (Code name: KRC-01)” in 2006. Since then, he has treated more than 250 patients with various types of solid tumor and published its safety and efficacy in many papers (see references).
Dr. Yasuhiro Ogawa obtained MD and PhD of Medicine from Kobe University. Currently, he serves as Director of Kochi General Rehabilitation Hospital. He is also a medical advisor for KORTUC.
How it all started and the story behind the R&D
214 Homer Ave, Palo Alto,
CA 94301, USA
4th Floor of the Shiroyama Trust Tower,
4-3-1 Toranomon, Minato-ku, Tokyo, 105-6004 Japan
